Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Sativex® Oromucosal Spray rescheduled in the UK

Bayer Healthcare has announced that the Home Office, after advice from the Advisory Council on the Misuse of Drugs’ (ACMD), has rescheduled Sativex® Oromucosal Spray in the UK. 

Bayer Healthcare has announced that the Home Office, after advice from the Advisory Council on the Misuse of Drugs’ (ACMD), has rescheduled Sativex® Oromucosal Spray in the UK. Sativex®, the first cannabinoid medicine derived from whole plant extracts from the cannabis sativa plant containing both delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), was approved by the MHRA in June 2010. At this time, Sativex® remained in Schedule 1 under a specific Home Office general licence. The ACMD has recommended that Sativex® be rescheduled to a Schedule 4, Part 1 substance. This will come into effect April 2013. Savitex indicated for patients with patients

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy